Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 …
…, KP Sugarman, P Peterson, WJ John, K Krejcy… - The Lancet, 2009 - thelancet.com
Background Several studies have shown the efficacy, tolerability, and ease of administration
of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-…
of pemetrexed—an antifolate antineoplastic agent—in patients with advanced non-small-…
Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its …
…, L Sivcheva, J Mayer, V Yablokova, K Krejcy… - The Lancet …, 2020 - thelancet.com
Background The PROUD-PV and CONTINUATION-PV trials aimed to compare the novel
monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for …
monopegylated interferon ropeginterferon alfa-2b with hydroxyurea, the standard therapy for …
Gemcitabine in non-small cell lung cancer (NSCLC)
C Manegold, P Zatloukal, K Krejcy, J Blatter - Investigational new drugs, 2000 - Springer
The role of chemotherapy in the treatment of non-smallcell lung cancer (NSCLC) has
increased greatly in the past fewyears. While cytotoxic drugs are currently used both as …
increased greatly in the past fewyears. While cytotoxic drugs are currently used both as …
[HTML][HTML] Chemotherapy for malignant pleural mesothelioma: past results and recent developments
S Tomek, S Emri, K Krejcy, C Manegold - British journal of cancer, 2003 - nature.com
This review summarises the results of previously conducted clinical trials, and subsequently
presents data arising from all phase II–III studies on chemotherapy of malignant pleural …
presents data arising from all phase II–III studies on chemotherapy of malignant pleural …
Non‐motor symptoms in Parkinson's disease are reduced by nabilone
…, R Stolz, K Krejcy, W Poewe, K Seppi… - Annals of …, 2020 - Wiley Online Library
Objective The objective of this study was to assess the efficacy and safety of nabilone, a
synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in …
synthetic tetrahydrocannabinol analogue, as a treatment for non‐motor symptoms (NMS) in …
[HTML][HTML] Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
…, L Sivcheva, J Mayer, V Yablokova, K Krejcy… - Leukemia, 2022 - nature.com
Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV)
but can diminish the mutant JAK2V617F allele burden [1, 2, 3]. After discontinuing long-…
but can diminish the mutant JAK2V617F allele burden [1, 2, 3]. After discontinuing long-…
Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, Pemetrexed disodium, ALIMTA™ and cisplatin: A multicenter phase II trial
…, J Von Pawel, R Pirker, R Malayeri, J Blatter, K Krejcy - Annals of oncology, 2000 - Elsevier
Background To evaluate the activity of MTA plus cisplatin in chemotherapy-naïve patients
with non-small cell lung cancer (NSCLC). Patients and methods Thirty-six chemotherapy-naïve …
with non-small cell lung cancer (NSCLC). Patients and methods Thirty-six chemotherapy-naïve …
Maintenance pemetrexed (Pem) plus best supportive care (BSC) versus placebo (Plac) plus BSC: A randomized phase III study in advanced non-small cell lung …
…, E Laack, YL Wu, P Peterson, K Krejcy… - Journal of Clinical …, 2009 - ascopubs.org
CRA8000 Background: Pemetrexed's efficacy, favorable tolerability profile, and ease of
administration provided a strong rationale for evaluation as maintenance therapy in patients (pts) …
administration provided a strong rationale for evaluation as maintenance therapy in patients (pts) …
[HTML][HTML] Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
…, L Sivcheva, J Mayer, V Yablokova, K Krejcy… - Leukemia, 2023 - nature.com
Patients with polycythemia vera (PV), an incurable Philadelphianegative myeloproliferative
neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution …
neoplasm, have shortened survival due to thrombohemorrhagic complications and evolution …
[HTML][HTML] Long-term use of ropeginterferon alpha-2b in polycythemia vera: 5-year results from a randomized controlled study and its extension
…, L Sivcheva, J Mayer, V Yablokova, K Krejcy… - Blood, 2020 - Elsevier
Introduction: Patients with polycythemia vera (PV) require life-long treatment to prevent
thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (…
thromboembolic events and minimize the risk of progression. Ropeginterferon alpha-2b (…